Search

Your search keyword '"Rieken, M."' showing total 334 results
Start Over Author "Rieken, M."
334 results on '"Rieken, M."'

7. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma

Author

Rieken, M., Schubert, T., Xylinas, E., Kluth, L., Rouprêt, M., Trinh, Q.-D., Lee, R.K., Al Hussein Al Awamlh, B., Fajkovic, H., Novara, G., Margulis, V., Lotan, Y., Martinez-Salamanca, J.I., Matsumoto, K., Seitz, C., Remzi, M., Karakiewicz, P.I., Scherr, D.S., Briganti, A., Bachmann, A., and Shariat, S.F.

Published
2014
Full Text
View/download PDF

9. Association between PRO 160/120 prescriptions and incidence of benign prostatic hyperplasia complications in Germany: a retrospective cohort study.

Author

Madersbacher, S, Rieken, M, Reuber, K, and Kostev, K

Subjects
BENIGN prostatic hyperplasia, RETENTION of urine, URINARY incontinence, LOGISTIC regression analysis, TAMSULOSIN, MEDICAL prescriptions, KEGEL exercises
Abstract

The present study aims to analyze the impact of PRO 160/120 prescriptions on the incidence of urinary incontinence, polyuria (including nocturia), urinary retention, and erectile dysfunction in a real-world setting in Germany and to compare these data with data for the 5-ARIs finasteride and dutasteride, and the α1-adrenoceptor antagonists tamsulosin and tamsulosin/dutasteride fixed-dose combination. This retrospective study was based on the IQVIA Disease Analyzer database and included male patients with an initial prescription of PRO 160/120, finasteride, dutasteride, tamsulosin, or tamsulosin/dutasteride fixed-dose combination between January 2010 and September 2020. Multivariable logistic regression analyses adjusted for age, health insurance, specialty, and relevant co-diagnoses were performed to estimate the association between PRO 160/120 prescriptions and incidence of pre-defined outcomes. A total of 77,923 patients were included in the study, 3,035 of whom received PRO 160/120. PRO 160/120 was significantly associated with reduced incidence of urinary incontinence (OR: 1.48; 95% CI: 1.10–1.98) and urinary retention compared to tamsulosin (OR: 3.39; 95% CI: 1.75–6.57 and tamsulosin/dutasteride (OR: 2.81; 95% CI: 1.35–5.82). Furthermore, PRO 160/120 significantly reduced the incidence of erectile dysfunction compared to dutasteride (OR: 2.79; 95% CI: 1.49–5.25). At the same time, patients receiving PRO 160/120 showed the same incidence of the remaining complications as those taking the reference substances. In conclusion, we observed a significant association between PRO 160/120 prescription and reduced incidence of urinary incontinence and urinary retention compared to tamsulosin and tamsulosin/dutasteride, as well as reduced incidence of erectile dysfunction compared to dutasteride. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms

Author

Malde, S., Umbach, R., Wheeler, J.R., Lytvyn, L., Cornu, J.-N., Gacci, M., Gratzke, C., Herrmann, T.R.W., Mamoulakis, C., Rieken, M., Speakman, M.J., Gravas, S., Drake, M.J., Guyatt, G.H., Tikkinen, K.A.O., HUS Abdominal Center, Department of Surgery, Urologian yksikkö, University of Helsinki, Helsinki University Hospital Area, and South Carelia Social and Health care District Eksote

Subjects
Investigation, PROSTATECTOMY, Patient, UNDERSTANDING PATIENT, Expectations, BENIGN PROSTATIC HYPERPLASIA, DECISION, Guideline, 3126 Surgery, anesthesiology, intensive care, radiology, Management, Treatment, MEDICAL-TREATMENT, PERSPECTIVES, MENS PREFERENCES, PROGRAM, Lower urinary tract symptoms, Values and preferences, Diagnostics, BEHAVIOR, Evidence, PHYSICIAN PERCEPTIONS
Abstract

Context: Understanding men's values and preferences in the context of personal, physical, emotional, relational, and social factors is important in optimising patient counselling, facilitating treatment decision-making, and improving guideline recommendations. Objective: To systematically review the available evidence regarding the values, preferences, and expectations of men towards the investigation and treatment (conservative, pharmacological, and surgical) of male lower urinary tract symptoms (LUTS). Evidence acquisition: We searched electronic databases until August 31, 2020 for quantitative and qualitative studies that reported values and preferences regarding the investigation and treatment of LUTS in men. We assessed the quality of evidence and risk of bias using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) and GRADE Confidence in the Evidence from Reviews of Qualitative Research (CERQual) approaches. Evidence synthesis: We included 25 quantitative studies, three qualitative studies, and one mixed-methods study recruiting 9235 patients. Most men reported urodynamic testing to be acceptable, despite discomfort or embarrassment, as it significantly informs treatment decisions (low certainty evidence). Men preferred conservative and less risky treatment options, but the preference varied depending on baseline symptom severity and the risk/benefit characteristics of the treatment (moderate certainty). Men preferred pharmacological treatments with a low risk of erectile dysfunction and those especially improving urgency incontinence (moderate certainty). Other important preference considerations included reducing the risk of acute urinary retention or surgery (moderate certainty). Conclusions: Men prefer lower-risk management options that have fewer sexual side effects and are primarily effective at improving urgency incontinence and nocturia. Overall, the evidence was rated to be of low to moderate certainty. This review can facilitate the treatment decision-making process and improve the trustworthiness of guideline recommendations. Patient summary: We thoroughly reviewed the evidence addressing men's values and preferences regarding the management of urinary symptoms and found that minimising adverse effects is particularly important. Further research to understand other factors that matter to men is required. (C) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Published
2021

14. Association between PRO 160/120prescriptions and incidence of benign prostatic hyperplasia complications in Germany: a retrospective cohort study

Author

Madersbacher, S, Rieken, M, Reuber, K, and Kostev, K

Abstract

ABSTRACTThe present study aims to analyze the impact of PRO 160/120prescriptions on the incidence of urinary incontinence, polyuria (including nocturia), urinary retention, and erectile dysfunction in a real-world setting in Germany and to compare these data with data for the 5-ARIs finasteride and dutasteride, and the α1-adrenoceptor antagonists tamsulosin and tamsulosin/dutasteride fixed-dose combination. This retrospective study was based on the IQVIA Disease Analyzer database and included male patients with an initial prescription of PRO 160/120, finasteride, dutasteride, tamsulosin, or tamsulosin/dutasteride fixed-dose combination between January 2010 and September 2020. Multivariable logistic regression analyses adjusted for age, health insurance, specialty, and relevant co-diagnoses were performed to estimate the association between PRO 160/120prescriptions and incidence of pre-defined outcomes. A total of 77,923 patients were included in the study, 3,035 of whom received PRO 160/120. PRO 160/120was significantly associated with reduced incidence of urinary incontinence (OR: 1.48; 95% CI: 1.10–1.98) and urinary retention compared to tamsulosin (OR: 3.39; 95% CI: 1.75–6.57 and tamsulosin/dutasteride (OR: 2.81; 95% CI: 1.35–5.82). Furthermore, PRO 160/120significantly reduced the incidence of erectile dysfunction compared to dutasteride (OR: 2.79; 95% CI: 1.49–5.25). At the same time, patients receiving PRO 160/120showed the same incidence of the remaining complications as those taking the reference substances. In conclusion, we observed a significant association between PRO 160/120prescription and reduced incidence of urinary incontinence and urinary retention compared to tamsulosin and tamsulosin/dutasteride, as well as reduced incidence of erectile dysfunction compared to dutasteride.

Published
2023
Full Text
View/download PDF

18. A systematic review of patients’ values, preferences and expectations for the diagnosis and treatment of male Lower Urinary Tract Symptoms (LUTS)

Author

Malde, S., primary, Umbach, R., additional, Wheeler, J.R., additional, Lytvyn, L., additional, Cornu, J-N., additional, Gacci, M., additional, Gratzke, C., additional, Herrmann, T.R.W., additional, Mamoulakis, C., additional, Rieken, M., additional, Speakman, M.J., additional, Gravas, S., additional, Drake, M.J., additional, Guyatt, G.H., additional, and Tikkinen, K.A.O., additional

Published
2021
Full Text
View/download PDF

23. Renales Aspergillom: Retroperitoneoskopische Exzision als minimal-invasive organerhaltende Therapieoption

Author

Wetterauer, C., Rieken, M., Müller, G., Bachmann, A., Bonkat, G., Wetterauer, C., Rieken, M., Müller, G., Bachmann, A., and Bonkat, G.

Abstract

Zusammenfassung: Aspergillusinfektionen bei immunkompromittierten Patienten sind häufig mit einer hohen Mortalität verbunden. Wir berichten über den Fall eines renalen Aspergilloms nach hämatopoetischer Stammzelltransplantation. Neben einer systemischen antimykotischen Therapie wurde eine chirurgische Intervention unumgänglich. Eine minimal-invasive, retroperitoneoskopische Resektion des Aspergilloms wurde durchgeführt.

Published
2019

24. Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis

Author

Karavitakis, M., primary, Kyriazis, I., additional, Omar, M.I., additional, Gravas, S., additional, Cornu, J-N., additional, Drake, M.J., additional, Gacci, M., additional, Gratzke, C., additional, Herrmann, T.R.W., additional, Madersbacher, S., additional, Rieken, M., additional, Speakman, M.J., additional, Tikkinen, K.A., additional, Yuan, Y., additional, and Mamoulakis, C., additional

Published
2019
Full Text
View/download PDF

25. Comparison of the roll-plate and sonication techniques in the diagnosis of microbial ureteral stent colonisation: results of the first prospective randomised study

Author

Bonkat, G., Braissant, O., Rieken, M., Müller, G., Frei, R., van der Merwe, Andre, Siegel, F., Gasser, T., Wyler, S., Bachmann, A., Widmer, A., Bonkat, G., Braissant, O., Rieken, M., Müller, G., Frei, R., van der Merwe, Andre, Siegel, F., Gasser, T., Wyler, S., Bachmann, A., and Widmer, A.

Abstract

Background: Microbial ureteral stent colonisation (MUSC) is one leading risk factor for complications associated with ureteral stent placement. As MUSC remains frequently undetected by standard urine cultures, its definitive diagnosis depends on microbiological investigation of the stent. However, a standard reference laboratory technique for studying MUSC is still lacking. Materials and methods: A total of 271 ureteral stents removed from 199 consecutive patients were investigated. Urine samples were obtained prior to device removal. Stents were divided into four parts. Each part was separately processed by the microbiology laboratory within 6h. Ureteral stents were randomly allocated to roll-plate or sonication, respectively, and analysed using standard microbiological techniques. Demographic and clinical data were prospectively collected using a standard case-report form. Results: Overall, roll-plate showed a higher detection rate of MUSC compared with sonication (35 vs. 28%, p<0.05) and urine culture (35 vs. 8%, p<0.05). No inferiority of Maki's technique was observed even when stents were stratified according to indwelling time below or above 30days. Compared with roll-plate, sonication commonly failed to detect Enterococcus spp., coagulase-negative staphylococci (CoNS) and Enterobacteriaceae. In addition, sonication required more hands-on time, more equipment and higher training than roll-plate in the laboratory. Conclusions: This prospective randomised study demonstrates the superiority of Maki's roll-plate technique over sonication in the diagnosis of MUSC and that urine culture is less sensitive than both methods. The higher detection rate, simplicity and cost-effectiveness render roll-plate the methodology of choice for routine clinical investigation as well as basic laboratory research

Published
2018

26. Laservaporisation der Prostata: Aktueller Stellenwert des Greenlight- und Diodenlasers

Author

Rieken, M., Bachmann, A., Gratzke, C., Rieken, M., Bachmann, A., and Gratzke, C.

Abstract

Zusammenfassung: Die Laservaporisation der Prostata hat sich in den letzten 10Jahren als sichere und effektive Alternative zur TURP etabliert. Die photoselektive Vaporisation der Prostata (PVP) hat seit der Einführung des 532nm 80-W-KTP-Lasers im Jahr 2002 maßgeblich zu dieser Entwicklung beigetragen. Ergebnisse prospektiv randomisierter Studien zu PVP und TURP mit einem maximalen Beobachtungszeitraum von 3Jahren zeigen mehrheitlich vergleichbare funktionelle Resultate. Zahlreiche Kohortenstudien belegen zudem die sichere Anwendung der PVP bei Patienten unter oraler Antikoagulation sowie bei großem Prostatavolumen. Zur Laservaporisation der Prostata mit dem Diodenlaser stehen Systeme verschiedener Hersteller zur Verfügung, welche sich in maximaler Laserleistung und Wellenlänge unterschieden. Daher kann nicht von dem Diodenlaser per se gesprochen werden. Bisher fehlen zu Diodenlasern Resultate prospektiv randomisierter Studien im Vergleich mit TURP. In Kohortenstudien oder Vergleichsstudien zur PVP zeichnet sich der Diodenlaser v.a. durch eine ausgeprägte Hämostase aus. Bezüglich der funktionellen Resultate zeigt sich ein uneinheitliches Bild mit teilweise hohen Reoperationsraten

Published
2018

27. Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

Author

Rentsch, C., primary, Bosshard, P., additional, Mayor, G., additional, Rieken, M., additional, Püschel, H., additional, Wirth, G., additional, Cathomas, R., additional, Grode, L., additional, Parzmair, G., additional, Eisele, B., additional, Sharma, H., additional, Shaligram, U., additional, Goldenberger, D., additional, Spertini, F., additional, Audran, R., additional, Enoui, M., additional, Berardi-Vilei, S., additional, Hayoz, S., additional, and Wicki, A., additional

Published
2018
Full Text
View/download PDF

28. Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision too

Author

Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, MONTORSI, FRANCESCO, Shariat SF, BRIGANTI , ALBERTO, Kluth, La, Abdollah, F, Xylinas, E, Rieken, M, Fajkovic, H, Sun, M, Karakiewicz, Pi, Seitz, C, Schramek, P, Herman, Mp, Becker, A, Loidl, W, Pummer, K, Nonis, A, Lee, Rk, Lotan, Y, Scherr, D, Seiler, D, Chun, Fk, Graefen, M, Tewari, A, Gönen, M, Montorsi, Francesco, Shariat, Sf, and Briganti, Alberto

Published
2014

29. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international multi-institutional study

Author

Rieken, M., primary, Kluth, L., additional, Xylinas, E., additional, Kaushik, D., additional, Boorjian, S., additional, Lotan, Y., additional, Roghmann, F., additional, Noldus, J., additional, Masson-Lecomte, A., additional, Vordos, D., additional, Hagiwara, M., additional, Kikuchi, E., additional, Ikeda, M., additional, Matsumoto, K., additional, Al Hussein Al Awamlh, B., additional, Bachmann, A., additional, Karakiewicz, P., additional, Rouprêt, M., additional, Scherr, D., additional, and Shariat, S.F., additional

Published
2016
Full Text
View/download PDF

34. Le rapport neutrophiles/lymphocytes est un facteur prédictif indépendant de récidive et de progression dans les tumeurs de vessie non infiltrantes

Author

Mbeutcha, A., primary, Lucca, I., additional, De martino, M., additional, Mathieu, R., additional, Rieken, M., additional, Xylinas, E., additional, Kluth, L., additional, Crivelli, J., additional, Lotan, Y., additional, Shariat, S., additional, Klatte, T., additional, and Karakiewicz, P., additional

Published
2015
Full Text
View/download PDF

35. 728 - Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

Author

Rentsch, C., Bosshard, P., Mayor, G., Rieken, M., Püschel, H., Wirth, G., Cathomas, R., Grode, L., Parzmair, G., Eisele, B., Sharma, H., Shaligram, U., Goldenberger, D., Spertini, F., Audran, R., Enoui, M., Berardi-Vilei, S., Hayoz, S., and Wicki, A.

Published
2018
Full Text
View/download PDF

36. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma

Author

Hudolin T, Kastelan Z, Ilic I, Levarda-Hudolin K, Basic-Jukic N, Rieken M, Spagnoli GC, Juretic A, Mengus C.

Subjects
MAGE, CTA, testicular lymphoma
Abstract

Background: Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the development of novel forms of therapy is urgently required. Specific immunotherapy generating immune responses directed against antigen predominantly expressed by cancer cells such as cancer-testis antigens (CTA) may provide a valid alternative treatment for patients bearing PTL, alone or in combination with current therapies. Methods: Three monoclonal antibodies (mAbs), 77B recognizing MAGE-A1, 57B recognizing an epitope shared by multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for immunohistochemical staining of 27 PTL, including 24 DLBCL. Results: Expression of MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher frequencies (54.17% and 37.50%, respectively) with different expression levels. Conclusions: These results suggest that MAGE-A and NY-ESO-1/LAGE-1, possibly in combination with other CTA, might be used as targets for specific immunotherapy in DLBCL.

Published
2013

38. 258 Improved detection and identification of urinary tract pathogens in immunosuppressed patients by combining Urine Flow-cytometry (UF) and Matrix-Assisted Laser Desorption/Ionization – Time Of Flight mass-spectrometry (MALDI-TOF)

Author

Bonkat, G., primary, Goldenberger, D., additional, Regeniter, A., additional, Halter, J., additional, Bachmann, A., additional, Rieken, M., additional, Müller, G., additional, Steiger, J., additional, Frei, R., additional, and Egli, A., additional

Published
2015
Full Text
View/download PDF

39. 647 The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: Validation and meta-analysis

Author

Lucca, I., primary, Shariat, S.F., additional, Rouprêt, M., additional, Rieken, M., additional, Kluth, L.A., additional, Mathieu, R., additional, Fajkovic, H., additional, Briganti, A., additional, Seitz, C., additional, Karakiewicz, P.I., additional, De Martino, M., additional, Lotan, Y., additional, Babjuk, M., additional, and Klatte, T., additional

Published
2015
Full Text
View/download PDF

41. 724 Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma

Author

Rieken, M., primary, Boorjian, S., additional, Kluth, L., additional, Xylinas, E., additional, Capitanio, U., additional, Briganti, A., additional, Thompson, H., additional, Leibovich, B., additional, Krabbe, L-M., additional, Margulis, V., additional, Raman, J., additional, Regelman, M., additional, Klatte, T., additional, Bachmann, A., additional, Karakiewicz, P., additional, Rouprêt, M., additional, Lee, R., additional, Gönen, M., additional, and Shariat, S.F., additional

Published
2015
Full Text
View/download PDF

42. 508 Association of cigarette smoking and smoking cessation with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

Author

Rieken, M., primary, Kluth, L., additional, Fajkovic, H., additional, Karakiewicz, P., additional, Lotan, Y., additional, Seitz, C., additional, Briganti, A., additional, Rouprêt, M., additional, Loidl, W., additional, Lee, R., additional, Trinh, Q-D., additional, Nyirady, P., additional, Bachmann, A., additional, Pourmand, G-R., additional, and Shariat, S.F., additional

Published
2015
Full Text
View/download PDF

44. 21 Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma

Author

Rieken, M., primary, Schubert, T., additional, Xylinas, E., additional, Kluth, L., additional, Rouprêt, M., additional, Quoc-Dien, T., additional, Lee, R.K., additional, Al Hussein Al Awamlh, B., additional, Fajkovic, H., additional, Novara, G., additional, Margulis, V., additional, Lotan, Y., additional, Martinez-Salamanca, J., additional, Matsumoto, K., additional, Seitz, C., additional, Remzi, M., additional, Karakiewicz, P., additional, Scherr, D., additional, Briganti, A., additional, Bachmann, A., additional, and Shariat, S.F., additional

Published
2014
Full Text
View/download PDF

45. 723 Clinical nodal staging scores for prostate cancer: A proposal for preoperative risk assessment

Author

Kluth, L.A., primary, Abdollah, F., additional, Xylinas, E., additional, Rieken, M., additional, Fajkovic, H., additional, Seitz, C., additional, Sun, M., additional, Karakiewicz, P., additional, Schramek, P., additional, Herman, M.P., additional, Becker, A., additional, Hansen, J., additional, Ehdaie, B., additional, Loidl, W., additional, Pummer, K., additional, Lee, R.K., additional, Lotan, Y., additional, Scherr, D.S., additional, Seiler, D., additional, Ahyai, S.A., additional, Graefen, M., additional, Tewari, A., additional, Nonis, A., additional, Bachmann, A., additional, Montorsi, F., additional, Gönen, M., additional, Briganti, A., additional, and Shariat, S.F., additional

Published
2014
Full Text
View/download PDF

46. 146 Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder

Author

Xylinas, E.N., primary, Cha, E., additional, Khani, F., additional, Kluth, L.A., additional, Rieken, M., additional, Volkmer, B.G., additional, Hautmann, R., additional, Küfer, R., additional, Chen, Y-T., additional, Rubin, M.A., additional, Zerbib, M., additional, Scherr, D.S., additional, Shariat, S.F., additional, and Robinson, B.D., additional

Published
2014
Full Text
View/download PDF

48. 126 Prognostic model for predicting survival in patients with disease recurrence following radical cystectomy

Author

Kluth, L.A., primary, Xylinas, E., additional, Rieken, M., additional, Kent, M., additional, Ikeda, M., additional, Matsumoto, K., additional, Hagiwara, M., additional, Kikuch, E., additional, Bing, M.T., additional, Gupta, A., additional, Sewell, J.M., additional, Konety, B.R., additional, Todenhöfer, T., additional, Schwentner, C., additional, Masson-Lecomte, A., additional, Vordos, D., additional, Roghmann, F., additional, Noldus, J., additional, Razmaria, A.A., additional, Smith, N.D., additional, Comploj, E., additional, Pycha, A., additional, Baniel, J., additional, Mano, R., additional, Novara, G., additional, Aziz, A., additional, Fritsche, H-M., additional, Brisuda, A., additional, Bivalacqua, T., additional, Gontero, P., additional, Boorjian, S.A., additional, Vickers, A., additional, and Shariat, S.F., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results